Vultaggio-Poma, Valentina
Scussel Bergamin, Leticia
Falzoni, Simonetta
Tarantini, Mario
Giuliani, Anna Lisa
Sandonà, Dorianna
Polverino De Laureto, Patrizia
Di Virgilio, Francesco
Funding for this research was provided by:
Università degli Studi di Ferrara
Article History
Received: 31 January 2023
Accepted: 5 April 2023
First Online: 19 April 2023
Declarations
:
: The authors declare no competing interests.
: Not applicable.
: FDV is a member of the Scientific Advisory Board of Biosceptre Ltd. (Australia), a biotech company involved in the development of anti-P2X7 antibodies, and a consultant with Breye Therapeutics ApS (Denmark). The other authors declare no conflict of interest.